AnaptysBio Quarterly Balance Sheet

NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD

45.95-0.26 (-0.56%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

AnaptysBio financial position

As of Mar 31, 2026, AnaptysBio reported total assets of $329.7 million, down 21.9% from a year earlier against total liabilities of $316.9 million. Shareholders' equity stood at $12.7 million, or 3.9% of assets. The company held $248.5 million in cash and equivalents.

The current ratio (current assets divided by current liabilities) was 7.58, meaning short-term assets cover obligations due within a year.

Summary generated from market data by MetaCap's automated system. Methodology

AnaptysBio balance sheet (quarterly)

AnaptysBio quarterly balance sheet
Quarter (USD)	Q1 20262026-03-31	Q4 20252025-12-31	Q3 20252025-09-30	Q2 20252025-06-30	Q1 20252025-03-31	Q4 20242024-12-31	Q3 20242024-09-30	Q2 20242024-06-30	Q1 20242024-03-31	Q4 20232023-12-31	Q3 20232023-09-30	Q2 20232023-06-30
Cash & Equivalents	248.47M	138.20M	109.83M	44.30M	98.64M	23.08M	191.58M	71.82M	53.70M	35.97M	26.30M	35.21M
Short-Term Investments	37.99M	73.44M	139.12M	221.41M	241.30M	262.29M	238.54M	278.98M	300.97M	354.94M	386.75M	394.28M
Receivables	25.75M	33.85M	75.69M	21.42M	17.88M	40.77M	12.20M	9.01M	7.09M	6.85M	3.27M	3.18M
Total Current Assets	316.11M	350.25M	330.65M	291.91M	363.11M	431.88M	448.68M	367.35M	372.42M	406.83M	428.00M	438.54M
Property, Plant & Equipment	1.28M	111.00K	1.50M	1.63M	1.74M	131.00K	1.73M	1.83M	1.95M	2.10M	2.25M	2.02M
Long-Term Investments	—	0	7.70M	28.00M	43.02M	35.47M	27.91M	42.65M	15.47M	27.03M	40.20M	59.24M
Total Assets	329.68M	364.39M	353.10M	335.25M	422.05M	483.83M	493.42M	427.38M	405.83M	452.39M	487.33M	517.10M
Accounts Payable	7.52M	3.87M	2.89M	3.33M	6.12M	4.00M	3.59M	4.89M	4.58M	4.70M	6.52M	4.76M
Total Current Liabilities	41.70M	38.63M	38.10M	35.53M	44.04M	45.43M	43.88M	40.42M	32.30M	37.44M	39.18M	41.63M
Total Liabilities	316.94M	327.19M	382.51M	379.98M	388.03M	412.97M	409.05M	417.50M	358.06M	364.29M	366.94M	368.65M
Shareholders' Equity	12.75M	37.21M	-29.42M	-44.73M	34.02M	70.87M	84.37M	9.88M	47.78M	88.10M	120.38M	148.45M
Retained Earnings	-825.44M	-772.56M	-822.17M	-837.29M	-798.66M	-759.33M	-737.54M	-704.69M	-658.03M	-614.10M	-571.88M	-534.58M
Net Cash (Debt)	286.45M	211.64M	248.96M	265.71M	339.94M	285.37M	430.12M	350.80M	354.67M	390.90M	413.05M	429.49M
Shares Outstanding	29.03M	28.02M	27.58M	27.97M	30.39M	30.47M	30.43M	27.43M	27.32M	26.60M	26.58M	26.53M

This table shows 12 quarterly periods of AnaptysBio's balance sheet, from Q1 2026 back to Q2 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a balance sheet?